What question did this study set out to answer?

The research aims to explore disease characteristics and treatment response in acute myeloid leukemia (AML) driven by RAS mutations.

December 8, 2025BloodOpen Access

RAS G12 and Q61 codon mutations confer distinct disease characteristics in Acute Myeloid Leukemia and exhibit differential response to RAS(ON) inhibitor RMC-7977.

View Full Paper

Ask AI

Bookmark

Authors

Experimental models show RAS mutations affect anemia and response to RMC-7977 in AML, suggesting varied treatment approaches.

The research aims to explore disease characteristics and treatment response in acute myeloid leukemia (AML) driven by RAS mutations.
Utilized inducible mutant mouse models with NrasG12D and NrasQ61R mutations.
Administered RMC-7977 or vehicle for 28 days to study disease progression and response.
Conducted in vitro experiments with RAS-mutant human AML cell lines to evaluate response to RMC-7977.
Double-mutant models showed more severe anemia and higher WBC counts than single mutants.
RMC-7977 reduced the number of leukemic colonies in a dose-dependent manner.
Differential responses to RMC-7977 suggested codon-specific effects on survival and signaling.

Wooten et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark